What gap in clinical trial technology led to development of specialized mobile infrastructure? A medical organisation approached Inventus with what appeared to be a routine request to source and deploy mobile devices for a clinical trial. The work itself was familiar. Co-Founder and CEO Steve Sanghera, and Co-Founder and Chairman Jim Michel had spent decades in telecommunications, managing mobile infrastructure across industries where systems are expected to perform reliably across geographies, networks and conditions. The assignment fell squarely within that experience. They delivered what was required. But a medical company was not a typical buyer of that scale of mobile infrastructure. It made them wonder: why would a clinical trial depend so heavily on devices not designed for it? Through conversations with trial sites, sponsors and operational teams, they learned that clinical trial devices were consumer-grade and were not built for regulated environments. Inventus chose to address that gap by rebuilding the system. It replaced consumer hardware with purpose-built patient- and site-specific devices designed for clinical trials. These devices introduced a standardised, validated foundation, ensuring that interactions with the study adhered to defined parameters rather than varying across users and environments. That decision established Inventus as the world’s first manufacturer dedicated exclusively to patient- and site-mobile technology for clinical trials, creating an entirely new category that did not previously exist. But solving the device layer exposed a second set of challenges. Once deployed into live trials, performance was no longer defined by the device alone. Data flow depended on connectivity across regions, and device behaviour depended on how it was controlled over time. These variables remained fragmented. Connectivity varied across networks. Control relied on adapting generic systems not designed for clinical protocols. Accountability sat across multiple vendors. The model was extended beyond hardware to build an integrated infrastructure around the device. Connectivity was redefined through Inventus Connect, the world’s first and only clinical data plan operator (CDPO). It ensured consistent, carrier-agnostic communication across geographies. Control was established through Inventus Control, the only mobile device management (MDM) platform purpose-built for clinical trials, enabling devices to operate in alignment with protocol requirements throughout the lifecycle of a study. “If you think about clinical trials as building a plane, sponsors and CROs design the engines and systems. We provide the rivets. Without those rivets, the plane doesn’t fly,” says Sanghera. Building the Missing Infrastructure Behind Clinical Trials How does integrated connectivity and device control improve consistency across global clinical trials? Each device enters the trial already connected. Provisioned with a global eSIM, it does not rely on a single carrier or require manual configuration as it moves across regions. Through Inventus Connect, devices remain connected across more than 150 countries, enabling eCOA data to be collected consistently and securely across borders. Connectivity adjusts in the background, allowing continuous communication regardless of location, while simplifying logistics and supporting reliable, cost-effective data management. Staying connected is only the first layer. Subsequent layers determine how each device is governed. Why is purpose-built mobile device management necessary for maintaining protocol alignment in studies? Before deployment, each device is configured through the MDM layer to align with the protocol of the study. Across Windows, iOS and Android environments, Inventus Control enables the creation and deployment of protocol-aligned settings, approved applications and locked-down controls. What a participant sees and how they interact with the device are defined in advance, ensuring consistency across sites while protecting data integrity. Device status, network connection and data transmission can be monitored in real time. If connectivity drops or behaviour shifts, the device can be accessed remotely and brought back into alignment. Software and application updates are deployed centrally, keeping devices in sync with study requirements without requiring physical intervention.

What principles have shaped long-term pharmaceutical development within medically led research organizations? Originality has defined Laboratori Baldacci S.p.A., an Italian pharmaceutical company, for more than a century. Founded in Pisa in 1904 by Dr Valentino Baldacci, it was built on one conviction. Only original, patented compounds validated through its own research earn a place in its portfolio. That principle has endured across generations of Baldacci family leadership, shaped by medical professionals. Pharmacologists, physicians and academic figures have guided its direction, reinforcing a model in which medical thinking drives development. Baldacci operates as a fully integrated organisation, combining internal research, patent-led development, controlled manufacturing and physician-focused scientific engagement. R&D is not a supporting function. It is the core of Baldacci’s identity, shaping how it identifies clinical gaps and strengthens the value of each therapy over time. Its portfolio of more than 10 product patents in more than 20 countries reflects its way of thinking. That structure is what moves differentiated compounds into clinical practice, particularly in gynaecology and neuro-psychiatry. “We don’t put new compounds on the market every year,” explains Marco Bertini, R&D and Medical Affairs Manager. “We try to reinforce the added value of the ones we have.” A Portfolio Built on Clinical Evidence How does integrated pharmaceutical research support development of clinically differentiated medical therapies today? Baldacci has worked with gynaecologists for over 50 years and with neuropsychiatrists for many years, developing original therapies in both areas. Research, chemical, analytical and manufacturing teams work in parallel from the start of each project, resolving formulation, pharmacokinetics and batch standardisati.